What question did this study set out to answer?

To evaluate the long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis after three years.

April 30, 2026Lara D. Veeken

P181 Long-term safety and tolerability of bimekizumab treatment across phase 2b and phase 3 studies in patients with axial spondyloarthritis or psoriatic arthritis: 3-year update from the phase 3 studies

View Full Paper

Ask AI

Bookmark

Authors

PMPhilip J MeaseProvidence College DPDenis PoddubnyyUniversity Health Network RBRajan Bajracharya

Discussion

Member takes

Implication

Long-term safety analysis of bimekizumab in axial spondyloarthritis and psoriatic arthritis patients shows no new safety signals, suggesting continued tolerability of the treatment.

Key Points

To evaluate the long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis after three years.
Analyzed long-term safety data from phase 2b and phase 3 studies and open-label extensions.
Compared exposure-adjusted incidence rates of treatment-emergent adverse events across studies.
Evaluated specific adverse events such as serious infections and fungal infections.
Safety profile remains consistent with previous analyses; no new safety signals identified.
Most frequent treatment-emergent adverse events included COVID-19 and upper respiratory tract infections.
Fungal infection rates were low, with oral candidiasis being the most common, leading to rare treatment discontinuation.

Cite This Study

Mease et al. (2026) studied this question.

synapsesocial.com/papers/69f2a4f18c0f03fd67764128 https://doi.org/10.1093/rheumatology/keag121.212

View Full Paper

Ask AI

Bookmark

Implication

Long-term safety analysis of bimekizumab in axial spondyloarthritis and psoriatic arthritis patients shows no new safety signals, suggesting continued tolerability of the treatment.

P181 Long-term safety and tolerability of bimekizumab treatment across phase 2b and phase 3 studies in patients with axial spondyloarthritis or psoriatic arthritis: 3-year update from the phase 3 studies

Discussion

Member takes

Implication

Key Points

Cite This Study

P181 Long-term safety and tolerability of bimekizumab treatment across phase 2b and phase 3 studies in patients with axial spondyloarthritis or psoriatic arthritis: 3-year update from the phase 3 studies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider